Research programme: antibody encoded oncolytic viruses - BioInvent/Transgene

Latest Information Update: 13 Dec 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator BioInvent International; Transgene
Class Antibodies; Antineoplastics; Oncolytic viruses
Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

06 Dec 2017 BioInvent International and Transgene enter a research collaboration to develop antibody encoded oncolytic viruses for Solid tumours
06 Dec 2017 Preclinical trials in Solid tumours in France and Sweden (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.